Advertisement
News
Advertisement

MagForce enters into preclinical research agreement to investigate NanoTherm(R) therapy in the gastrointestinal cancer field in the USA

Thu, 06/21/2012 - 11:45pm
The Associated Press

MagForce AG / MagForce enters into preclinical research agreement to

investigate NanoTherm@ therapy in the gastrointestinal cancer field in

the USA

. Processed and transmitted by Thomson Reuters ONE.

The issuer is solely responsible for the content of this announcement.

? Goal is to achieve preclinical proof-of-concept in pancreatic and

liver Cancer

? First important milestone to set up a clinical development program

with Key Opinion Leaders of the Mayo Clinic and throughout the US

? A previous pilot study conducted at the Charité, Berlin, has shown

feasibility for NanoTherm@ therapy in patients with pancreatic cancer

MagForce AG (Frankfurt, XETRA: MF6), a leading medical device company

in the field of nanomedicine with focus on oncology, announced today

that the Company has entered into a pre-clinical research agreement

with Mayo Clinic (Rochester, MN), a leading US medical center.

Under the terms of the agreement, Mayo Clinic will start a research

program applying MagForce's NanoTherm@ therapy to investigate the

preclinical efficacy of the therapy in pancreatic and liver cancer.

The project will be directed by Dev Mukhopadhyay, Professor of

Biochemistry/Molecular Biology, and the study will be funded by Mayo

Clinic. The goal of the project is to achieve preclinical

proof-of-concept in order to file the clinical development program

supporting the FDA PMA (FDA premarket approval) of the NanoTherm@

therapy in these indications.

"Pancreatic cancer is one of the most aggressive diseases in oncology,

ranking fourth among the tumor related causes of death. It is mostly

recognized in a late and advanced status and consequently called "the

silent killer". Due to the poor overall survival rates and the severe

side effects of chemotherapeutics, the current standard of care, this

disease is an enormous challenge in oncology. With approximately

32,000 new cases annually in the US alone there is a very high medical

need to develop new therapeutic options for the treatment of these

desperate patients," said Prof Dr Hoda Tawfik, Vice President

R&D/Medical Affairs at MagForce. "In a pilot study MagForce could show

the feasibility of the use of its NanoTherm@ therapy in pancreatic

cancer patients with first hints of activity. I am delighted that we

are now teaming up with the highly prestigious cancer center Mayo

Clinic to achieve preclinical proof-of-concept in pancreatic and liver

cancer with our innovative technology. A positive outcome of this new

project would be the first important milestone to set up a clinical

development program in gastrointestinal cancer in cooperation with

medical key opinion leaders throughout the United States," added Prof

Dr Hoda Tawfik.

This research agreement is a significant step in engaging the US

medical community in the development of the NanoTherm@ Therapy," added

Dr Andreas Jordan, Executive Board and Founder of MagForce.

About MagForce AG

MagForce AG is a leading medical technology company in the field of

nanomedicine in oncology. The Company's proprietary, NanoTherm@

therapy, enables the targeted treatment of solid tumors through the

intratumoral generation of heat via activation of magnetic

nanoparticles. NanoTherm@, NanoPlan@, and NanoActivator? are

components of the therapy and have received EU-wide regulatory

approval as medical devices for the treatment of brain tumors.

MagForce, NanoTherm@, NanoPlan@, and NanoActivator? are trademarks of

MagForce AG in select countries. For more information, please visit

www.magforce.com(http://www.magforce.com).

About NanoTherm@ Therapy

The NanoTherm@ therapy is a new approach for the local treatment of

solid tumors. The principle of the method is the direct introduction

of magnetic nanoparticles into a tumor and their subsequent heating in

an alternating magnetic field. The water soluble nanoparticles are

extremely small (approximately 15 nanometers in diameter), and contain

an iron oxide core with an aminosilane coating. The particles are

activated by a magnetic field that changes its polarity 100,000 times

per second and heat is produced. Depending on the duration of

treatment and the achieved intratumoral temperatures, the tumor cells

are either directly destroyed (thermal ablation) or sensitized for

concomitant chemo or radiotherapy (hyperthermia). With this new

procedure, it is possible to combat the tumor from the inside out,

thereby sparing surrounding healthy tissue. The nanoparticles remain

in place at the treatment area, allowing for repeat treatments and the

integration of multimodal therapy concepts. NanoTherm@ therapy has

regulatory approval in 27 European countries.

Disclaimer

This release may contain forward-looking statements and information

which may be identified by formulations using terms such as "expects",

"aims", "anticipates", "intends", "plans", "believes", "seeks",

"estimates" or "will". Such forward-looking statements are based on

our current expectations and certain assumptions, which may be subject

to a variety of risks and uncertainties. The results actually achieved

by MagForce AG may substantially differ from these forward-looking

statements. MagForce AG assumes no obligation to update these

forward-looking statements or to correct them in case of developments,

which differ from those, anticipated.

MagForce_Press Release_Mayo Clinic_June 22, 2012:

http://hugin.info/143761/R/1621460/518166.pdf(http://hugin.info/143761/R/1621460/518166.pdf)

This announcement is distributed by Thomson Reuters on behalf of

Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other

applicable laws; and (ii) they are solely responsible for the content,

accuracy and originality of the information contained therein.

Source: MagForce AG via Thomson Reuters ONE [HUG#1621460]

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading